MingSight Completes a New Round of Financing to Accelerate Clinical Development in Chronic Lymphocytic Leukemia and Diabetic Macular Edema
Retrieved on:
Friday, November 12, 2021
Biotechnology, Pharmaceutical, Optical, Finance, Health, Diabetes, Professional Services, Clinical Trials, PKC, PK, Safety, Protein kinase C, Lists of diseases, Degenerative disease, PLCG2, MD, CRT, Digital technology, Neuroscience, CEO, Diabetic retinopathy, MBA, Inflammation, CSO, Artificial intelligence, Program, Chronic lymphocytic leukemia, BTK, DME, Trust, VEGF, Ophthalmology, Visual acuity, Doctor of Philosophy, Lymphoid leukemia, Skin, Patient, CLL, Kidney, Retina, Pharmaceutical industry, MS-553, MingSight Pharmaceuticals, Kaitai Capital, MS-553, MINGSIGHT PHARMACEUTICALS, KAITAI CAPITAL
The proceeds will be used for the clinical development of MS-553, a new generation inhibitor of protein kinase C (PKC) beta for the treatment of Chronic lymphocytic Leukemia (CLL) and Diabetic Macular Edema (DME).
Key Points:
- The proceeds will be used for the clinical development of MS-553, a new generation inhibitor of protein kinase C (PKC) beta for the treatment of Chronic lymphocytic Leukemia (CLL) and Diabetic Macular Edema (DME).
- We greatly appreciate the trust and support of our investors, said Kai Zhang, MD, MBA, CEO and Co-founder of MingSight.
- We look forward to working with Kaitai and our other investors to accelerate the development of this unique compound.
- MingSight is a clinical stage company focused on developing differentiated, novel therapies for serious diseases including B-cell malignancies, diabetic macular edema, and autoimmune diseases.